Thomas K. Hansen

1 ta ish

Novo Nordisk (Denmark)

1. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

   Christopher Sorli, Shin‐ichi Harashima, George Tsoukas +4

   Maqola20172 iqtibos

   ABIABI:AkademIndex/2026.other.778473